Evaluation of pharmacokinetic-pharmacodynamic (PKPD) relationship of an oral, selective, first-in-class, potent IDH2 inhibitor, AG-221, from a phase 1 trial in patients with advanced IDH2 mutant positive hematologic malignancies

Category Primary study
JournalBlood
Year 2014
This article has no abstract
Epistemonikos ID: 4d572a437545cf03edc4c51af30a8a600a29906c
First added on: Feb 06, 2025